Dimitri G Trembath1, Eric S Davis2, Shanti Rao3, Evan Bradler3, Angelica F Saada4, Bentley R Midkiff5, Anna C Snavely2, Matthew G Ewend2,6, Frances A Collichio2,7, Carrie B Lee2,7, Georgia-Sofia Karachaliou7, Fatih Ayvali7, David W Ollila2,8, Michal T Krauze9, John M Kirkwood9, Benjamin G Vincent2,7, Nana Nikolaishvilli-Feinberg5, Stergios J Moschos2,7. 1. Departments of Pathology and Laboratory Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States. 2. Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States. 3. University of North Carolina School of Medicine, Chapel Hill, NC, United States. 4. State University of New York Downstate Medical Center College of Medicine, Brooklyn, NY, United States. 5. Translational Pathology Laboratory, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States. 6. Department of Neurosurgery, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States. 7. Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States. 8. Department of Surgery, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States. 9. Melanoma and Skin Cancer Program, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.
Abstract
BACKGROUND: High tumor-infiltrating lymphocytes (TILs) and hemorrhage are important prognostic factors in patients who have undergone craniotomy for melanoma brain metastases (MBM) before 2011 at the University of Pittsburgh Medical Center (UPMC). We have investigated the prognostic or predictive role of these histopathologic factors in a more contemporary craniotomy cohort from the University of North Carolina at Chapel Hill (UNC-CH). We have also sought to understand better how various immune cell subsets, angiogenic factors, and blood vessels may be associated with clinical and radiographic features in MBM. METHODS: Brain tumors from the UPMC and UNC-CH patient cohorts were (re)analyzed by standard histopathology, tumor tissue imaging, and gene expression profiling. Variables were associated with overall survival (OS) and radiographic features. RESULTS: The patient subgroup with high TILs in craniotomy specimens and subsequent treatment with immune checkpoint inhibitors (ICIs, n=7) trended to have longer OS compared to the subgroup with high TILs and no treatment with ICIs (n=11, p=0.059). Bleeding was significantly associated with tumor volume before craniotomy, high melanoma-specific expression of basic fibroblast growth factor (bFGF), and high density of CD31+αSMA- blood vessels. Brain tumors with high versus low peritumoral edema before craniotomy had low (17%) versus high (41%) incidence of brisk TILs. Melanoma-specific expression of the vascular endothelial growth factor (VEGF) was comparable to VEGF expression by TILs and was not associated with any particular prognostic, radiographic, or histopathologic features. A gene signature associated with gamma delta (gd) T cells was significantly higher in intracranial than same-patient extracranial metastases and primary melanoma. However, gdT cell density in MBM was not prognostic. CONCLUSIONS: ICIs may provide greater clinical benefit in patients with brisk TILs in MBM. Intratumoral hemorrhage in brain metastases, a significant clinical problem, is not merely associated with tumor volume but also with underlying biology. bFGF may be an essential pathway to target. VEGF, a factor principally associated with peritumoral edema, is not only produced by melanoma cells but also by TILs. Therefore, suppressing low-grade peritumoral edema using corticosteroids may harm TIL function in 41% of cases. Ongoing clinical trials targeting VEGF in MBM may predict a lack of unfavorable impacts on TIL density and/or intratumoral hemorrhage.
BACKGROUND: High tumor-infiltrating lymphocytes (TILs) and hemorrhage are important prognostic factors in patients who have undergone craniotomy for melanoma brain metastases (MBM) before 2011 at the University of Pittsburgh Medical Center (UPMC). We have investigated the prognostic or predictive role of these histopathologic factors in a more contemporary craniotomy cohort from the University of North Carolina at Chapel Hill (UNC-CH). We have also sought to understand better how various immune cell subsets, angiogenic factors, and blood vessels may be associated with clinical and radiographic features in MBM. METHODS: Brain tumors from the UPMC and UNC-CH patient cohorts were (re)analyzed by standard histopathology, tumor tissue imaging, and gene expression profiling. Variables were associated with overall survival (OS) and radiographic features. RESULTS: The patient subgroup with high TILs in craniotomy specimens and subsequent treatment with immune checkpoint inhibitors (ICIs, n=7) trended to have longer OS compared to the subgroup with high TILs and no treatment with ICIs (n=11, p=0.059). Bleeding was significantly associated with tumor volume before craniotomy, high melanoma-specific expression of basic fibroblast growth factor (bFGF), and high density of CD31+αSMA- blood vessels. Brain tumors with high versus low peritumoral edema before craniotomy had low (17%) versus high (41%) incidence of brisk TILs. Melanoma-specific expression of the vascular endothelial growth factor (VEGF) was comparable to VEGF expression by TILs and was not associated with any particular prognostic, radiographic, or histopathologic features. A gene signature associated with gamma delta (gd) T cells was significantly higher in intracranial than same-patient extracranial metastases and primary melanoma. However, gdT cell density in MBM was not prognostic. CONCLUSIONS: ICIs may provide greater clinical benefit in patients with brisk TILs in MBM. Intratumoral hemorrhage in brain metastases, a significant clinical problem, is not merely associated with tumor volume but also with underlying biology. bFGF may be an essential pathway to target. VEGF, a factor principally associated with peritumoral edema, is not only produced by melanoma cells but also by TILs. Therefore, suppressing low-grade peritumoral edema using corticosteroids may harm TIL function in 41% of cases. Ongoing clinical trials targeting VEGF in MBM may predict a lack of unfavorable impacts on TIL density and/or intratumoral hemorrhage.
Authors: Wolfgang Wick; Thierry Gorlia; Martin Bendszus; Martin Taphoorn; Felix Sahm; Inga Harting; Alba A Brandes; Walter Taal; Julien Domont; Ahmed Idbaih; Mario Campone; Paul M Clement; Roger Stupp; Michel Fabbro; Emilie Le Rhun; Francois Dubois; Michael Weller; Andreas von Deimling; Vassilis Golfinopoulos; Jacoline C Bromberg; Michael Platten; Martin Klein; Martin J van den Bent Journal: N Engl J Med Date: 2017-11-16 Impact factor: 91.245
Authors: D Kondziolka; M Bernstein; L Resch; C H Tator; J F Fleming; R G Vanderlinden; H Schutz Journal: J Neurosurg Date: 1987-12 Impact factor: 5.115
Authors: Gina Song; David B Darr; Charlene M Santos; Mark Ross; Alain Valdivia; Jamie L Jordan; Bentley R Midkiff; Stephanie Cohen; Nana Nikolaishvili-Feinberg; C Ryan Miller; Teresa K Tarrant; Arlin B Rogers; Andrew C Dudley; Charles M Perou; William C Zamboni Journal: Clin Cancer Res Date: 2014-09-17 Impact factor: 12.531
Authors: Grant M Fischer; Ali Jalali; David A Kircher; Won-Chul Lee; Jennifer L McQuade; Lauren E Haydu; Aron Y Joon; Alexandre Reuben; Mariana P de Macedo; Fernando C L Carapeto; Chendong Yang; Anuj Srivastava; Chandrashekar R Ambati; Arun Sreekumar; Courtney W Hudgens; Barbara Knighton; Wanleng Deng; Sherise D Ferguson; Hussein A Tawbi; Isabella C Glitza; Jeffrey E Gershenwald; Y N Vashisht Gopal; Patrick Hwu; Jason T Huse; Jennifer A Wargo; P Andrew Futreal; Nagireddy Putluri; Alexander J Lazar; Ralph J DeBerardinis; Joseph R Marszalek; Jianjun Zhang; Sheri L Holmen; Michael T Tetzlaff; Michael A Davies Journal: Cancer Discov Date: 2019-02-20 Impact factor: 39.397
Authors: Guo Chen; Nitin Chakravarti; Kimberly Aardalen; Alexander J Lazar; Michael T Tetzlaff; Bradley Wubbenhorst; Sang-Bae Kim; Scott Kopetz; Alicia A Ledoux; Y N Vashisht Gopal; Cristiano Goncalves Pereira; Wanleng Deng; Ju-Seog Lee; Katherine L Nathanson; Kenneth D Aldape; Victor G Prieto; Darrin Stuart; Michael A Davies Journal: Clin Cancer Res Date: 2014-05-06 Impact factor: 12.531
Authors: Moritz Felcht; Robert Luck; Alexander Schering; Philipp Seidel; Kshitij Srivastava; Junhao Hu; Arne Bartol; Yvonne Kienast; Christiane Vettel; Elias K Loos; Simone Kutschera; Susanne Bartels; Sila Appak; Eva Besemfelder; Dorothee Terhardt; Emmanouil Chavakis; Thomas Wieland; Christian Klein; Markus Thomas; Akiyoshi Uemura; Sergij Goerdt; Hellmut G Augustin Journal: J Clin Invest Date: 2012-05-15 Impact factor: 14.808
Authors: Xiaobei Zhao; Anyou Wang; Vonn Walter; Nirali M Patel; David A Eberhard; Michele C Hayward; Ashley H Salazar; Heejoon Jo; Matthew G Soloway; Matthew D Wilkerson; Joel S Parker; Xiaoying Yin; Guosheng Zhang; Marni B Siegel; Gary B Rosson; H Shelton Earp; Norman E Sharpless; Margaret L Gulley; Karen E Weck; D Neil Hayes; Stergios J Moschos Journal: PLoS One Date: 2015-06-15 Impact factor: 3.240
Authors: Thuy T Tran; Amit Mahajan; Veronica L Chiang; Sarah B Goldberg; Don X Nguyen; Lucia B Jilaveanu; Harriet M Kluger Journal: J Immunother Cancer Date: 2019-07-30 Impact factor: 13.751
Authors: Dimitri G Trembath; Anastasia Ivanova; Michal T Krauze; John M Kirkwood; Nana Nikolaishvilli-Feinberg; Stergios J Moschos Journal: Melanoma Res Date: 2021-06-01 Impact factor: 3.199
Authors: Georgia Sofia Karachaliou; Rached Alkallas; Sarah B Carroll; Chongshan Caressi; Danny Zakria; Nirali M Patel; Dimitri G Trembath; Jennifer A Ezzell; Guillaume J Pegna; Paul B Googe; Jonathan P Galeotti; Fatih Ayvali; Frances A Collichio; Carrie B Lee; David W Ollila; Margaret L Gulley; Douglas B Johnson; Kevin B Kim; Ian R Watson; Stergios J Moschos Journal: BMC Cancer Date: 2022-01-05 Impact factor: 4.430
Authors: Peter Solar; Michal Hendrych; Martin Barak; Hana Valekova; Marketa Hermanova; Radim Jancalek Journal: Front Cell Neurosci Date: 2022-07-15 Impact factor: 6.147